- Home
- LFT vs TELA Comparison
LFT vs TELA Comparison
Compare LFT & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFT | TELA |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8M | 31.4M |
| IPO Year | 2012 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LFT | TELA |
|---|---|---|
| Price | $4.52 | $1.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $2.08 |
| AVG Volume (30 Days) | 34.0K | ★ 196.2K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | ★ 35.71% | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $80,275,000.00 |
| Revenue This Year | $168.78 | N/A |
| Revenue Next Year | N/A | $9.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $4.38 | $0.50 |
| 52 Week High | $69.35 | $1.56 |
Technical Indicators
Market Signals| Indicator | LFT | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 44.77 | 45.11 |
| Support Level | N/A | $0.61 |
| Resistance Level | $5.83 | $1.25 |
| Average True Range (ATR) | 0.34 | 0.12 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 14.78 | 12.60 |
Price Performance
Historical ComparisonAbout LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About TELA TELA Bio Inc.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.